title: Expression and characterization of recombinant human antithrombin III in Pichia pastoris.
abstract: Antithrombin III (ATIII) is a member of the serpin superfamily and a major regulator of the blood coagulation cascade. To express recombinant human ATIII (rATIII) in the methylotrophic yeast Pichia pastoris, we constructed an rATIII expression plasmid which contained the ATIII cDNA encoding mature protein region connected with the truncated mAOX2 promoter and the SUC2 secretion signal, introduced it into the P. pastoris genome, and screened for a single copy transformant. The secretion of rATIII from the transformant reached a level of 320 IU/L in the culture broth at 169 h. From the culture-supernatant, rATIII was purified to over 99% by heparin-affinity chromatography and other column chromatography methods. We characterized rATIII and compared it with human plasma-derived ATIII (pATIII). The purified rATIII possessed correct N-terminal amino acid sequence, and its molecular weight by SDS-PAGE of 56,000 Da was slightly different from the 58,000 Da of pATIII. Sequence and mass spectrometry analysis of BrCN fragments revealed that posttranslational modifications had occurred in rATIII. O-linked mannosylation was found at Ser 3 and Thr 9, and in some rATIII molecules, modification with O-linked mannosyl-mannose had probably occurred at Thr 386, close to the reactive center. Although the heparin-binding affinity of rATIII was 10-fold higher than that of pATIII, its inhibitory activity against thrombin was only half. As the conformation of rATIII and pATIII by circular dichroism spectroscopy was similar, O-glycosylation in the reactive center loop was assumed to be mainly responsible for the decreased inhibitory activity. pATIII can inactivate thrombin through formation of a stable thrombin-ATIII complex, but rATIII modified with O-glycosylation in the reactive center loop may act as a substrate rather than an inhibitor of thrombin.
authors.affiliation: Pharmaceutical Research Division, Drug Discovery Laboratories, Welfide Corporation, 2-25-1 Shodai-ohtani, Hirakata, Osaka, 573-1153, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Mochizuki
authors.forename: N
authors.initials: N
authors.lastname: Hamato
authors.forename: M
authors.initials: M
authors.lastname: Hirose
authors.forename: K
authors.initials: K
authors.lastname: Miyano
authors.forename: W
authors.initials: W
authors.lastname: Ohtani
authors.forename: S
authors.initials: S
authors.lastname: Kameyama
authors.forename: S
authors.initials: S
authors.lastname: Kuwae
authors.forename: T
authors.initials: T
authors.lastname: Tokuyama
authors.forename: H
authors.initials: H
authors.lastname: Ohi
mesh_terms: D000990:Antithrombin III / Q000096:biosynthesis* / Q000737:chemistry / Q000494:pharmacology; D003001:Cloning, Molecular / Q000379:methods*; D065427:Factor Xa Inhibitors; D006031:Glycosylation; D006493:Heparin / Q000378:metabolism; D006801:Humans; D010843:Pichia / Q000235:genetics*; D010957:Plasmids / Q000235:genetics; D011485:Protein Binding; D011487:Protein Conformation; D011499:Protein Processing, Post-Translational; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000737:chemistry / Q000494:pharmacology; D020539:Sequence Analysis, Protein; D013917:Thrombin / Q000037:antagonists & inhibitors; D014162:Transfection
chemical_list: D065427:Factor Xa Inhibitors; D011994:Recombinant Proteins; D000990:Antithrombin III; D006493:Heparin; D013917:Thrombin